Cogent Biosciences, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Cogent Biosciences, Inc. (COGT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-10
- Cogent Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $628.00K, a 25.10% increase year-over-year.
- Cogent Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $529.00K, a 6.22% increase year-over-year.
- Cogent Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $513.00K, a 6.21% increase year-over-year.
- Cogent Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $506.00K, a 6.08% increase year-over-year.
- Cogent Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $2.02M, a 6.21% increase from fiscal 2024.
- Cogent Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.90M, a 44.23% increase from fiscal 2023.
- Cogent Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.32M, a 73.83% decline from fiscal 2022.
- Cogent Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $5.04M, a 173.10% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $628.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.16M 10-Q · filed 2026-08-10 | $1.67M derived: sum of 3 quarters · filed 2026-08-10 | $2.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $529.00K 10-Q · filed 2026-05-05 | $1.04M derived: sum of 2 quarters · filed 2026-05-05 | $1.55M derived: sum of 3 quarters · filed 2026-05-05 | $2.05M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $513.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.02M derived: sum of 2 quarters · filed 2026-02-17 | $1.52M derived: sum of 3 quarters · filed 2026-08-10 | $2.02M 10-K · filed 2026-02-17 |
| 2025-09-30 | $506.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.01M derived: sum of 2 quarters · filed 2026-08-10 | $1.51M 10-Q · filed 2025-11-07 | $1.99M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $502.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.00M 10-Q · filed 2026-08-10 | $1.48M derived: sum of 3 quarters · filed 2026-08-10 | $1.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $498.00K 10-Q · filed 2026-05-05 | $981.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.46M derived: sum of 3 quarters · filed 2026-05-05 | $1.93M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $960.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.43M derived: sum of 3 quarters · filed 2026-02-17 | $1.90M 10-K · filed 2026-02-17 |
| 2024-09-30 | $477.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $951.00K derived: sum of 2 quarters · filed 2025-11-07 | $1.42M 10-Q · filed 2025-11-07 | $1.61M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $474.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $941.00K 10-Q · filed 2025-08-05 | $1.14M derived: sum of 3 quarters · filed 2026-02-17 | $1.41M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $467.00K 10-Q · filed 2025-05-06 | $663.00K derived: sum of 2 quarters · filed 2026-02-17 | $937.00K derived: sum of 3 quarters · filed 2026-02-17 | $1.59M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $470.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.12M derived: sum of 3 quarters · filed 2026-02-17 | $1.32M 10-K · filed 2026-02-17 |
| 2023-09-30 | $274.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $928.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.12M 10-Q · filed 2024-11-12 | $1.64M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $654.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $848.00K 10-Q · filed 2024-08-06 | $1.36M derived: sum of 3 quarters · filed 2025-02-25 | $4.82M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $194.00K 10-Q · filed 2024-05-07 | $711.00K derived: sum of 2 quarters · filed 2025-02-25 | $4.17M derived: sum of 3 quarters · filed 2025-02-25 | $4.74M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $517.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $3.97M derived: sum of 2 quarters · filed 2025-02-25 | $4.54M derived: sum of 3 quarters · filed 2025-02-25 | $5.04M 10-K · filed 2025-02-25 |
| 2022-09-30 | $3.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $4.03M derived: sum of 2 quarters · filed 2023-11-07 | $4.52M 10-Q · filed 2023-11-07 | $5.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $573.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.06M 10-Q · filed 2023-08-08 | $1.54M derived: sum of 3 quarters · filed 2024-02-26 | $2.01M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $491.00K 10-Q · filed 2023-05-09 | $969.00K derived: sum of 2 quarters · filed 2024-02-26 | $1.44M derived: sum of 3 quarters · filed 2024-02-26 | |
| 2021-12-31 | $478.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $944.00K derived: sum of 2 quarters · filed 2024-02-26 | $1.84M 10-K · filed 2024-02-26 | |
| 2021-09-30 | $466.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.37M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $900.00K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |